A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-Small Cell Lung Cancer
- Determine the response in patients with stage IIIB or IV or recurrent non-small cell
lung cancer treated with suberoylanilide hydroxamic acid.
- Determine the time to progression and overall survival of patients treated with this
- Determine the toxicity profile of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses
repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 1 month and then every 3
months for 1 year or until disease progression.
PROJECTED ACCRUAL: A total of 23 patients will be accrued for this study within 11-18
Masking: Open Label, Primary Purpose: Treatment
Antitumor response rate as assessed by RECIST criteria
Anne M. Traynor, MD
University of Wisconsin, Madison
United States: Federal Government
|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center||Madison, Wisconsin 53792-6164|